Skip to main content

Hindson Benjamin J.'s Form 4 filing

10x Genomics, Inc. (TXG) · filed Jan 5, 2022

Accession no.
0001567619-22-000621
Filed
Jan 5, 2022
Trade date
Jan 3, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 2 derivative transactions. Open-market sales total $6.09M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hindson Benjamin J.CIK 0001786391Director, Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2022Class A Common StockMOption exerciseAcquired+2,084$11.48+$23,924.32162,770Direct
Jan 3, 2022Class A Common StockMOption exerciseAcquired+39,582$74.58+$2,952,025.56202,352Direct
Jan 3, 2022Class A Common StockSSaleDisposed−2,300$144.56F2−$332,488200,052Direct
Jan 3, 2022Class A Common StockSSaleDisposed−16,464$145.43F3−$2,394,359.52183,588Direct
Jan 3, 2022Class A Common StockSSaleDisposed−17,396$146.29F4−$2,544,860.84166,192Direct
Jan 3, 2022Class A Common StockSSaleDisposed−2,906$147.34F5−$428,170.04163,286Direct
Jan 3, 2022Class A Common StockSSaleDisposed−2,000$148.44F6−$296,880161,286Direct
Jan 3, 2022Class A Common StockSSaleDisposed−600$149.24F7−$89,544160,686Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2022Class A Common StockMOption exerciseDisposed−2,084$0.00$031,250Direct
Jan 3, 2022Class A Common StockMOption exerciseDisposed−39,582$0.00$093,630Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $143.89 to $144.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $144.89 to $145.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $145.89 to $146.8725. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F5

This transaction was executed in multiple trades at prices ranging from $146.89 to $147.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $147.93 to $148.925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $149.09 to $149.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Remarks

Chief Scientific Officer and President

Read the full filing on SEC EDGAR (opens in a new tab)